NEW YORK, Jan. 12 (GenomeWeb News) - Genizon BioSciences will use Illumina's whole-genome genotyping platform for its disease-association research program, Illumina said today.
Genizon will conduct whole genome-association studies on at least 16,000 case and control samples in 11 common diseases over the next year and a half, Illumina said. Genizon has completed three such studies.
DNA samples will be collected in collaboration with over 900 clinical investigators in Quebec. Genizon will use a custom version of Illumina's Sentrix HumanHap300 BeadChip, tailored to genetic sharing in the Quebec population, to query over 350,000 SNP loci per sample.
Genizon will expand its existing Illumina system with six additional BeadArray Readers, extensive automation, LIMS to integrate workflows, and new BeadStudio software.